1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Common Mechanisms in Autoimmunity Grants is sponsored by Breakthrough T1D (formerly JDRF), Lupus Research Alliance, and National Multiple Sclerosis Society. This grant program invites innovative ideas that address needs across multiple autoimmune diseases in novel ways. The objective is to develop new insights into the common mechanisms driving autoimmune diseases and accelerate the advancement of novel therapeutic strategies.
It seeks proposals from investigators across autoimmune and other relevant fields to advance the understanding of autoimmunity and obtain more specific insights into commonalities and differences of immune pathways governing these disease processes.
Get alerted about grants like this
Save a search for “Breakthrough T1D (formerly JDRF), Lupus Research Alliance, and National Multiple Sclerosis Society” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Investigators across autoimmune and other relevant fields. Confirm the full requirements in the official notice before applying.
Common Mechanisms in Autoimmunity Grants is funded by Breakthrough T1D (formerly JDRF), Lupus Research Alliance, and National Multiple Sclerosis Society. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
S. 3971 reauthorized SBIR/STTR through 2031 after the longest lapse in the program's history. Buried inside are a new $30M Strategic Breakthrough Award, per-company proposal caps arriving in FY2027, eight-watchlist foreign-risk screening, and bigger TABA budgets. Here is what each change means for who wins and who gets squeezed out.
Read articleNSF restarted its SBIR/STTR programs on May 31, 2026 after a multi-month hiatus, with a $250 million FY26 allocation, a Project Pitch portal reopen on June 2, and a first full-proposal deadline of July 27, 2026. The big structural changes: a new Strategic Breakthrough tier that extends invited Phase II companies up to $30 million, and a $40 million pilot for next-generation scientific instrumentation. Phase I tops out at $305K, Phase II at $1.25M, with November 4 and March 4, 2027 windows behind the July 27 first deadline. For deep-tech startups that watched the NIH SBIR omnibus go dark and DARPA pull back on conventional Phase II slots, this is the most consequential reopening of the year — and the Strategic Breakthrough tier is the first time NSF has competed directly with venture capital at growth-stage check sizes.
Read articleOn May 31, NSF announced the restart of its SBIR and STTR programs with a \$250 million FY26 allocation, a Project Pitch portal reopening June 2, a first full-proposal deadline of July 27, 2026, and additional windows on November 4 and March 4, 2027. Phase I tops out at \$305K, Phase II at \$1.25M, and a new Strategic Breakthrough lane extends invited Phase II companies up to \$30M. A separate \$40M instrumentation pilot (NSF 26-511) funds next-generation scientific tools. Here is what changed from prior cycles, who the program actually fits, and how to position a Project Pitch for the July deadline.
Read article